Advertisement

Cancer Immunology, Immunotherapy

, Volume 68, Issue 5, pp 753–763 | Cite as

Expression of a soluble IL-10 receptor enhances the therapeutic effects of a papillomavirus-associated antitumor vaccine in a murine model

  • Jamile R. Silva
  • Natiely S. Sales
  • Mariângela O. Silva
  • Luana R. M. M. Aps
  • Ana C. R. Moreno
  • Elaine G. Rodrigues
  • Luís C. S. FerreiraEmail author
  • Mariana O. Diniz
Original Article
  • 131 Downloads

Abstract

The presence of IL-10, produced either by tumor cells or immunosuppressive cells, is frequently associated with a poor prognosis for cancer progression. It may also negatively impact anticancer treatments, such as immunotherapies, that otherwise would promote the activation of cytotoxic T cells capable of detecting and destroying malignant cells. In the present study, we evaluated a new adjuvant approach for anticancer immunotherapy using a plasmid vector encoding a soluble form of the IL-10 receptor (pIL-10R). pIL-10R was coadministered to mice with a DNA vaccine encoding the type 16 human papillomavirus (HPV-16) E7 oncoprotein genetically fused with glycoprotein D of herpes simplex virus (HSV) (pgDE7h). Immunization regimens based on the coadministration of pIL-10R and pgDE7h enhanced the antitumor immunity elicited in mice injected with TC-1 cells, which express HPV-16 oncoproteins. The administration of the DNA vaccines by in vivo electroporation further enhanced the anticancer effects of the vaccines, leading to the activation of tumor-infiltrating polyfunctional E7-specific cytotoxic CD8+ T cells and control of the expansion of immunosuppressive cells. In addition, the combination of immunotherapy and pIL-10R allowed the control of tumors in more advanced growth stages that otherwise would not be treatable by the pgDE7h vaccine. In conclusion, the proposed treatment involving the expression of IL-10R enhanced the antitumor protective immunity induced by pgDE7h administration and may contribute to the development of more efficient clinical interventions against HPV-induced tumors.

Keywords

Cancer DNA vaccine IL-10 gDE7 TC-1 cells Cancer immunotherapy 

Abbreviations

ATCC

American Type Culture Collection

CAPES

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior

CEUA

Ethics Committee on the Use of Animals in Experimentation

c-Ha-Ras

v-Ha-ras Harvey rat sarcoma viral oncogene homolog

CNPq

Conselho Nacional de Desenvolvimento Científico e Tecnológico

CONCEA

National Council for Control of Animal Experimentation

E6

Early protein 6

E7

Early protein 7

EP

Electroporation

FAPESP

Fundação de Amparo à Pesquisa do Estado de São Paulo

FSC

Forward scatter

gD

Glycoprotein D

ICGEB

International Centre for Genetic Engineering and Biotechnology

mAb

Monoclonal antibodies

PBMC

Peripheral blood mononuclear cell

pgDE7h

Vaccine plasmid composed of gD fused to HPV-16 E7

pIL-10R

Interleukin-10 receptor plasmid

SSC

Side scatter

Notes

Acknowledgements

We thankfully acknowledge the technical support of Eduardo Gimenes Martins and Carolina Bertelli.

Author contributions

JRS, MD and LCSF conceived the study and the experimental design. MOD supervised the experimental work. JRS, NSS, MOS, LRMMA, ACRM, and MOD carried out the experiments, processed the experimental data, and participated in the interpretation of the results. EGR discussed the results and contributed to the writing of the manuscript. JRS wrote the manuscript with support from MOD and LCSF.

Funding

This study was supported by funds from the Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) and University of São Paulo (USP). Jamile R. Silva was a fellow supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), Grant 2014/11073-1; Natiely S. Sales was a fellow supported by FAPESP, grant 2016/14344-1; Mariângela O. Silva was a fellow supported by FAPESP, Grant 2016/11397-7; Luana R. M. M. Aps was a fellow supported by FAPESP, Grant 2013/15360-2; Ana C. R. Moreno was a fellow supported by FAPESP, Grants 2015/16505-0 and 2016/00708-1 and supported by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Grant 560713; Mariana O. Diniz was a fellow supported by FAPESP, grant 2011/51218-0; Luís C. S. Ferreira was a fellow supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Grant 520931/1996-3. Elaine G. Rodrigues was a fellow supported by CNPq, Grant 308085/2015-9.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical approval

All handling procedures were performed according to the protocol approved by the Ethics Committee on the Use of Animals (CEUA) of the Institute of Biomedical Sciences of the University of São Paulo (Brazil) on August 18, 2014 (project number 92/2014) and according to standard rules approved by the National Council for Control of Animal Experimentation (CONCEA), Brazil.

Animal source

Six–eight-week-old C57BL/6 mice were purchased from the Animal Breeding Center of the Institute of Biomedical Sciences of the University of São Paulo (Brazil) and housed in the Animal Facility at the same Institute.

Cell line authentication

The TC-1 cell line was originally created and kindly provided by Dr. T.C. Wu, Johns Hopkins University, Baltimore, MD, USA. The cells tested negative for mycoplasma by PCR and were cultured for no more than 2 weeks after thawing. The cells showed consistent morphologies and growth rates prior to use in in vivo experiments. The cells tested positive for the expression of the HPV-16 E6 and E7 proteins by Western blotting. The TC-1 cell line is not currently available from the ATCC bank.

Supplementary material

262_2018_2297_MOESM1_ESM.pdf (232 kb)
Supplementary material 1 (PDF 232 KB)

References

  1. 1.
    Yaddanapudi K, Mitchell RA, Eaton JW (2013) Cancer vaccines: looking to the future. Oncoimmunology 2:1–7.  https://doi.org/10.4161/onci.23403 CrossRefGoogle Scholar
  2. 2.
    Azar KK, Tani M, Yasuda H et al (2004) Increased secretion patterns of interleukin-10 and tumor necrosis factor-alpha in cervical squamous intraepithelial lesions. Hum Pathol 35:1376–1384.  https://doi.org/10.1016/j.humpath.2004.08.012 CrossRefGoogle Scholar
  3. 3.
    Bermudez-Morales VH, Gutierrez LX, Alcocer-Gonzalez JM et al (2008) Correlation between IL-10 gene expression and HPV infection in cervical cancer: a mechanism for immune response escape. Cancer Invest 26:1037–1043.  https://doi.org/10.1080/07357900802112693 CrossRefGoogle Scholar
  4. 4.
    Syrjänen S, Naud P, Sarian L et al (2009) Immunosuppressive cytokine Interleukin-10 (IL-10) is up-regulated in high-grade CIN but not associated with high-risk human papillomavirus (HPV) at baseline, outcomes of HR-HPV infections or incident CIN in the LAMS cohort. Virchows Arch 455:505–515.  https://doi.org/10.1007/s00428-009-0850-7 CrossRefGoogle Scholar
  5. 5.
    Berti FCB, Pereira APL, Cebinelli GCM et al (2017) The role of interleukin 10 in human papilloma virus infection and progression to cervical carcinoma. Cytokine Growth Factor Rev 34:1–13.  https://doi.org/10.1016/j.cytogfr.2017.03.002 CrossRefGoogle Scholar
  6. 6.
    Alcocer-González JM, Berumen J, Taméz-Guerra R et al (2006) In Vivo expression of immunosuppressive cytokines in human papillomavirus-transformed cervical cancer cells. Viral Immunol 19:481–491.  https://doi.org/10.1089/vim.2006.19.481 CrossRefGoogle Scholar
  7. 7.
    Chuang C-Y, Sung W-W, Wang L et al (2012) Differential Impact of IL-10 expression on survival and relapse between HPV16-positive and -negative oral squamous cell carcinomas. PLoS One 7:e47541.  https://doi.org/10.1371/journal.pone.0047541 CrossRefGoogle Scholar
  8. 8.
    Bornstein S, Schmidt M, Choonoo G et al (2016) IL-10 and integrin signaling pathways are associated with head and neck cancer progression. BMC Genom 17:38.  https://doi.org/10.1186/s12864-015-2359-6 CrossRefGoogle Scholar
  9. 9.
    Chen L, Qiu M, He W et al (2012) Functional study of immature dendritic cells co-transfected with IL-10 and TGF-beta 1 genes in vitro. Mol Biol Rep 39:6633–6639.  https://doi.org/10.1007/s11033-012-1468-4 CrossRefGoogle Scholar
  10. 10.
    ten Broeke T, Wubbolts R, Stoorvogel W (2013) MHC class II antigen presentation by dendritic cells regulated through endosomal sorting. Cold Spring Harb Perspect Biol 5:a016873.  https://doi.org/10.1101/cshperspect.a016873 CrossRefGoogle Scholar
  11. 11.
    Maldonado RA, von Andrian UH (2010) How tolerogenic dendritic cells induce regulatory T cells. Adv Immunol 108:111–165.  https://doi.org/10.1016/B978-0-12-380995-7.00004-5 CrossRefGoogle Scholar
  12. 12.
    García-Rocha R, Moreno-Lafont M, Mora-García ML et al (2015) Mesenchymal stromal cells derived from cervical cancer tumors induce TGF-β1 expression and IL-10 expression and secretion in the cervical cancer cells, resulting in protection from cytotoxic T cell activity. Cytokine 76:382–390.  https://doi.org/10.1016/j.cyto.2015.09.001 CrossRefGoogle Scholar
  13. 13.
    Sevko A, Umansky V (2013) Myeloid-derived suppressor cells interact with tumors in terms of myelopoiesis, tumorigenesis and immunosuppression: Thick as thieves. J Cancer 4:3–11.  https://doi.org/10.7150/jca.5047 CrossRefGoogle Scholar
  14. 14.
    Song X, Guo W, Cui J et al (2011) A tritherapy combination of a fusion protein vaccine with immune-modulating doses of sequential chemotherapies in an optimized regimen completely eradicates large tumors in mice. Int J Cancer 128:1129–1138.  https://doi.org/10.1002/ijc.25451 CrossRefGoogle Scholar
  15. 15.
    Kim JH, Kang TH, Noh KH et al (2011) Blocking the immunosuppressive axis with small interfering RNA targeting interleukin (IL)-10 receptor enhances dendritic cell-based vaccine potency. Clin Exp Immunol 165:180–189.  https://doi.org/10.1111/j.1365-2249.2011.04410.x CrossRefGoogle Scholar
  16. 16.
    Ahn YH, Hong SO, Kim JH et al (2015) The siRNA cocktail targeting interleukin 10 receptor and transforming growth factor-β receptor on dendritic cells potentiates tumour antigen-specific CD8 + T cell immunity. Clin Exp Immunol 181:164–178.  https://doi.org/10.1111/cei.12620 CrossRefGoogle Scholar
  17. 17.
    Marchi LHL, Paschoalin T, Travassos LR, Rodrigues EG (2011) Gene therapy with interleukin-10 receptor and interleukin-12 induces a protective interferon-γ-dependent response against B16F10-Nex2 melanoma. Cancer Gene Ther 18:110–122.  https://doi.org/10.1038/cgt.2010.58 CrossRefGoogle Scholar
  18. 18.
    Diniz MO, Cariri FAMO, Aps LRMM, Ferreira LCS (2013) Enhanced therapeutic effects conferred by an experimental DNA vaccine targeting human papillomavirus-induced tumors. Hum Gene Ther 24:861–870.  https://doi.org/10.1089/hum.2013.102 CrossRefGoogle Scholar
  19. 19.
    Porchia BFMM, Diniz MO, Cariri FAMO et al (2011) Purified herpes simplex type 1 glycoprotein D (gD) genetically fused with the type 16 human papillomavirus E7 oncoprotein enhances antigen-specific CD8 + T cell responses and confers protective antitumor immunity. Mol Pharm 8:2320–2330.  https://doi.org/10.1021/mp200194s CrossRefGoogle Scholar
  20. 20.
    Diniz MO, Lasaro MO, Ertl HC, Ferreira LCS (2010) Immune responses and therapeutic antitumor effects of an experimental DNA vaccine encoding human papillomavirus type 16 oncoproteins genetically fused to herpesvirus glycoprotein D. Clin Vaccine Immunol 17:1576–1583.  https://doi.org/10.1128/CVI.00264-10 CrossRefGoogle Scholar
  21. 21.
    Lin KY, Guarnieri FG, Staveley-O’Carroll KF et al (1996) Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56:21–26Google Scholar
  22. 22.
    Diniz MO, Sales NS, Silva JR, Ferreira LCS (2016) Protection against HPV-16-associated tumors requires the activation of CD8 + effector memory T cells and the control of myeloid-derived suppressor cells. Mol Cancer Ther 15:1920–1930.  https://doi.org/10.1158/1535-7163.MCT-15-0742 CrossRefGoogle Scholar
  23. 23.
    Lee S-H, Danishmalik SN, Sin J-I (2015) DNA vaccines, electroporation and their applications in cancer treatment. Hum Vaccin Immunother 11:1889–1900.  https://doi.org/10.1080/21645515.2015.1035502 CrossRefGoogle Scholar
  24. 24.
    Ni G, Wang T, Walton S et al (2015) Manipulating IL-10 signalling blockade for better immunotherapy. Cell Immunol 293:126–129.  https://doi.org/10.1016/j.cellimm.2014.12.012 CrossRefGoogle Scholar
  25. 25.
    Gothelf A, Gehl J (2012) What you always needed to know about electroporation based DNA vaccines. Hum Vaccin Immunother 8:1694–1702.  https://doi.org/10.4161/hv.22062 CrossRefGoogle Scholar
  26. 26.
    Sales NS, Silva JR, Aps LRMM et al (2017) In vivo electroporation enhances vaccine-mediated therapeutic control of human papilloma virus-associated tumors by the activation of multifunctional and effector memory CD8 + T cells. Vaccine.  https://doi.org/10.1016/j.vaccine.2017.11.011 Google Scholar
  27. 27.
    Trimble CL, Morrow MP, Kraynyak KA et al (2015) Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: A randomised, double-blind, placebo-controlled phase 2b trial. Lancet 386:2078–2088.  https://doi.org/10.1016/S0140-6736(15)00239-1 CrossRefGoogle Scholar
  28. 28.
    De Rosa SC, Lu FX, Yu J et al (2004) Vaccination in humans generates broad T cell cytokine responses. J Immunol 173:5372–5380CrossRefGoogle Scholar
  29. 29.
    Precopio ML, Betts MR, Parrino J et al (2007) Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med 204:1405–1416.  https://doi.org/10.1084/jem.20062363 CrossRefGoogle Scholar
  30. 30.
    Rizzuto GA, Merghoub T, Hirschhorn-Cymerman D et al (2009) Self-antigen-specific CD8 + T cell precursor frequency determines the quality of the antitumor immune response. J Exp Med 206:849–866.  https://doi.org/10.1084/jem.20081382 CrossRefGoogle Scholar
  31. 31.
    Kim TJ, Jin H-T, Hur S-Y et al (2014) Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients. Nat Commun 5:5317.  https://doi.org/10.1038/ncomms6317 CrossRefGoogle Scholar
  32. 32.
    Li O (2013) The paradox of IL–10–mediated modulation in cervical cancer (Review). Biomed Reports.  https://doi.org/10.3892/br.2013.69 Google Scholar
  33. 33.
    Wilke CM, Wei S, Wang L et al (2011) Dual biological effects of the cytokines interleukin-10 and interferon-γ. Cancer Immunol Immunother 60:1529–1541.  https://doi.org/10.1007/s00262-011-1104-5 CrossRefGoogle Scholar
  34. 34.
    Santin AD, Hermonat PL, Ravaggi A et al (2000) Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papillomavirus-specific CD8(+) cytotoxic T lymphocytes. J Virol 74:4729–4737CrossRefGoogle Scholar
  35. 35.
    Wang Y, Liu X-H, Li Y-H, Li O (2013) The paradox of IL-10-mediated modulation in cervical cancer. Biomed Rep 1:347–351.  https://doi.org/10.3892/br.2013.69 CrossRefGoogle Scholar
  36. 36.
    Li L, Ma Y, Liu S et al (2016) Interleukin 10 promotes immune response by increasing the survival of activated CD8 + T cells in human papillomavirus 16-infected cervical cancer. Tumor Biol 37:16093–16101.  https://doi.org/10.1007/s13277-016-5466-3 CrossRefGoogle Scholar
  37. 37.
    Chen S, Ni G, Wu X et al (2016) Blocking IL-10 signalling at the time of immunization renders the tumour more accessible to T cell infiltration in mice. Cell Immunol 300:9–17.  https://doi.org/10.1016/j.cellimm.2015.11.002 CrossRefGoogle Scholar
  38. 38.
    Ahrends T, Baba a N, Xiao Y et al (2016) CD27 agonism plus PD-1 blockade recapitulates CD4 + T-cell help in therapeutic anticancer vaccination. Cancer Res 76:2921–2931.  https://doi.org/10.1158/0008-5472.CAN-15-3130 CrossRefGoogle Scholar
  39. 39.
    Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G (2013) Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 73:3591–3603.  https://doi.org/10.1158/0008-5472.CAN-12-4100 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Jamile R. Silva
    • 1
  • Natiely S. Sales
    • 1
  • Mariângela O. Silva
    • 1
  • Luana R. M. M. Aps
    • 1
  • Ana C. R. Moreno
    • 1
  • Elaine G. Rodrigues
    • 2
  • Luís C. S. Ferreira
    • 1
    Email author
  • Mariana O. Diniz
    • 1
    • 3
  1. 1.Vaccine Development Laboratory, Department of Microbiology, Biomedical Sciences InstituteUniversity of São PauloSão PauloBrazil
  2. 2.Tumor Immunobiology Laboratory, Department of Microbiology, Immunology and Parasitology, Escola Paulista de MedicinaFederal University of São PauloSão PauloBrazil
  3. 3.Division of Infection and ImmunityUniversity College LondonLondonUK

Personalised recommendations